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Introduction: Development of resistance to tamoxifen is an important clinical issue in the treatment of breast
cancer. Tamoxifen resistance may be the result of acquisition of epigenetic regulation within breast cancer cells,
such as DNA methylation, resulting in changed mRNA expression of genes pivotal for estrogen-dependent growth.
Alternatively, tamoxifen resistance may be due to selection of pre-existing resistant cells, or a combination of the
two mechanisms.
Methods: To evaluate the contribution of these possible tamoxifen resistance mechanisms, we applied modified
DNA methylation-specific digital karyotyping (MMSDK) and digital gene expression (DGE) in combination with
massive parallel sequencing to analyze a well-established tamoxifen-resistant cell line model (TAMR), consisting of 4
resistant and one parental cell line. Another tamoxifen-resistant cell line model system (LCC1/LCC2) was used to
validate the DNA methylation and gene expression results.
Results: Significant differences were observed in global gene expression and DNA methylation profiles between
the parental tamoxifen-sensitive cell line and the 4 tamoxifen-resistant TAMR sublines. The 4 TAMR cell lines exhibited
higher methylation levels as well as an inverse relationship between gene expression and DNA methylation in the
promoter regions. A panel of genes, including NRIP1, HECA and FIS1, exhibited lower gene expression in resistant vs.
parental cells and concurrent increased promoter CGI methylation in resistant vs. parental cell lines. A major part of
the methylation, gene expression, and pathway alterations observed in the TAMR model were also present in the
LCC1/LCC2 cell line model. More importantly, high expression of SOX2 and alterations of other SOX and E2F gene
family members, as well as RB-related pocket protein genes in TAMR highlighted stem cell-associated pathways as
being central in the resistant cells and imply that cancer-initiating cells/cancer stem-like cells may be involved in
tamoxifen resistance in this model.
Conclusion: Our data highlight the likelihood that resistant cells emerge from cancer-initiating cells/cancer stem-like
cells and imply that these cells may gain further advantage in growth via epigenetic mechanisms. Illuminating the
expression and DNA methylation features of putative cancer-initiating cells/cancer stem cells may suggest novel
strategies to overcome tamoxifen resistance.* Correspondence: bolundlars@gmail.com; hditzel@health.sdu.dk
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Around 80% of breast cancer patients present with pri-
mary breast tumors that are estrogen receptor (ER)
alpha-positive, suggesting that the tumor is dependent
on estrogen for growth [1,2]. Accordingly, most of these
patients are offered endocrine therapy, which currently
consists of the anti-estrogen tamoxifen or aromatase in-
hibitors. These drugs can be used successfully both in
the adjuvant and advanced disease settings. Tamoxifen
belongs to the selective ER modulator class of drugs
that act both as antagonists and as agonists in an
ER-dependent and tissue-dependent manner [3]. For ex-
ample, in breast cancer tissue, tamoxifen acts as a com-
petitive estrogen antagonist by competing with estrogen
for binding to ER, thereby inhibiting the growth of
estrogen-dependent breast cancer cells [4]. However,
about one-third of primary ER-positive breast tumors do
not benefit from adjuvant tamoxifen treatment, resulting
in disease recurrence [5]. In metastatic disease, disease
progression eventually occurs in most patients receiving
tamoxifen treatment.
Acquired endocrine resistance is suggested to develop
as a result of a complex set of molecular changes, including
specific gene expression alterations, and/or modifications
and loss of ER [6]. These changes have been observed in
in vitro models of tamoxifen resistance and in ER-positive
breast cancer patients with recurrent disease following
endocrine treatment [7]. As it is currently not possible to
predict sensitivity/resistance to endocrine treatment in
ER-positive breast cancer patients, new tests to identify
endocrine-resistant ER-positive breast cancer are being
developed using different molecular markers [8].
Several distinct molecular mechanisms may lead to
tamoxifen resistance, and within individual tumors differ-
ent cancer cells may use different mechanisms, complicat-
ing the evaluation of tamoxifen resistance mechanism(s)
when examining whole tumor samples. These obstacles
have led to studies of isogenic tamoxifen-resistant breast
cancer cell line model systems that may have some advan-
tages in pinpointing individual resistance mechanisms. The
estrogen-responsive and tamoxifen-sensitive human breast
cancer cell line MCF-7 [9,10] and its derived tamoxifen-
resistant sub-lines MCF-7/TAMR-1, MCF-7/TAMR-4,
MCF-7/TAMR-7 and MCF-7/TAMR-8 [11,12] constitute a
well-established in vitro model that has been used to iden-
tify several proteins potentially involved in signaling path-
ways associated with tamoxifen resistance in ER-positive
breast cancer cells; for example, phosphorylated Akt,
PKCα, PKCδ, EGFR and HER2 [13-15]. A number of these
proteins have been positively validated in clinical studies
[16-18]. Tamoxifen resistance in the TAMR cell lines was
developed by culturing the parental cell line in an initial
high dose of tamoxifen (1 μM). In contrast, tamoxifen re-
sistance in the LCC1/LCC2 cell line model system wasdeveloped by incrementally increased doses of tamoxifen
to the parental cell line MCF7/LCC1 (estrogen inde-
pendent and tamoxifen sensitive) [19].
Epigenetic alterations, which include modifications of
DNA, histones and chromatin, play an important role
in transcription regulation. Epigenetic changes are re-
versible and can occur quickly during environmental
changes [20]. Increasing evidence indicates that these
epigenetic alterations, particularly DNA methylation, may
be used as future markers for diagnosis, prognosis and pre-
diction of response to therapies [21]. A few studies have
suggested that epigenetic alterations may also play a role in
tamoxifen resistance in breast cancer [22,23]. Recently,
cancer stem cells were also reported to be associated with
cancer therapy resistance [24]. There are thus three hy-
potheses in the development of tamoxifen resistance: first,
ER-positive breast cancer cells can acquire tamoxifen re-
sistance by epigenetic alternation resulting in changed
mRNA expression of genes pivotal for estrogen-dependent
growth; second, tamoxifen resistance develops due to se-
lection of preexisting cancer initiating cells/cancer stem-
like cells; and third, tamoxifen resistance results from a
combination of the above hypotheses – that is, by selection
of preexisting resistant cells that gain or repress gene ex-
pression to acquire further advantage in growth via epigen-
etic mechanisms, such as changed DNA methylation.
To test the above hypotheses, we applied modified
DNA methylation-specific digital karyotyping (MMSDK)
[25] and digital gene expression (DGE) in combination
with next-generation parallel sequencing to analyze
methylation and gene expression profiles of the parent
MCF-7 breast cancer cell line and its tamoxifen-resistant
TAMR cell lines (see Additional file 1 for a description
and an illustration of the MMSDK methods). The resulting
methylation data were compared with the corresponding
gene expression profiles. In addition, methylation and gene
expression alterations identified in the TAMR cell line
model were validated in the LCC1/LCC2 tamoxifen-
resistant cell line model.
Methods
TAMR cell line model
The MCF-7 human breast cancer cell line was originally
received from The Breast Cancer Task Force Cell Culture
Bank, Mason Research Institute (Worcester, MA, USA).
The MCF-7 cells were gradually adapted to grow in
low serum concentration (initially 0.5% fetal calf serum
(FCS) and 1% FCS after phenol red was omitted from the
culture medium [11]), and the tamoxifen-sensitive sub-
line MCF-7/S0.5 [26] was used to establish tamoxifen-
resistant (TAMR) cell lines by extended treatment with
1 μM tamoxifen, as described previously [11,26]. The
four TAMR cell lines, MCF-7/TAMR-1 (TAMR-1), MCF-
7/TAMR-4 (TAMR-4), MCF-7/TAMR-7 (TAMR-7) and
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colonies that emerged in cultures of MCF-7/S0.5 cells
treated with 1 μM tamoxifen [11,27]. The TAMR cell
lines were maintained in Dulbecco’s modified Eagle’s
medium/F12 (1:1) supplemented with 1% FCS and 1 μM
tamoxifen, as detailed by Thrane and colleagues [28].
Tamoxifen had a weak agonistic effect (20 to 80% in-
crease after 5 days) on growth of the tamoxifen-resistant
cell lines [28]. Withdrawal of tamoxifen for up to 15
weeks did not change the growth characteristics of the
TAMR-1 cell line, demonstrating a stable resistant pheno-
type [11]. The cells were kept within 10 passages through-
out the experiment to reduce possible variability between
experimental results.
LCC1/LCC2 cell line model
The estrogen-independent, but tamoxifen-responsive,
LCC1 cell line was established from the hormone-
dependent parent cell line MCF-7 through prolonged
withdrawal from potent estrogenic stimuli both in vivo
and in vitro [29]. The in vivo selected cell line was further
passaged in ovariectomized athymic nude mice and re-
established in vitro to generate a new cell line, MCF-7/
LCC1, which is also estrogen independent but is similarly
tamoxifen responsive as its parent cell line [30]. Further-
more, the new cell estrogen-independent, tamoxifen-
resistant sub-line LCC2 [19] was developed through
growth of LCC1 in incrementally increased dosages of
tamoxifen in vitro. LCC1 and LCC2 were cultured in
Dulbecco’s modified Eagle’s medium/F12 without phenol
red, supplemented with dextran charcoal-stripped 5% FCS
and 1% penicillin/streptomycin. The cells were maintained
at 37°C in a humidified atmosphere of 95% ambient air
and 5% carbon dioxide. Genomic DNA and total RNA
were isolated from LCC1 and LCC2.
Modified DNA methylation-specific digital karyotyping
For optimized MMSDK library construction, the BssHII
restriction enzyme (New England Biolabs, Hitchin, UK) was
selected. This enzyme has 52,167 recognition sites in the
human genome, but only unmethylated sites are cleaved.
The sites are preferentially located in CpG islands and
promoters in the human genome, thus providing higher
resolution for mapping DNA methylation in the human
genome than previous methods [25].
In silico digital digestion of the unmethylated human gen-
ome with BssHII and NlaIII was performed. The distribu-
tion of the lengths of the theoretically generated BssHII/
NlaIII fragments was calculated and the majority of frag-
ments were shorter than 1,000 base pairs (bp), with a fre-
quency peak at 50 to 150 bp. Within CpG islands (CGIs),
23,818 BssHII recognition sites were identified, accounting
for 45.7% of all BssHII recognition sites in the human gen-
ome. Our approach also allowed determination of themethylation state of CpGs in repeat sequences. According
to RepeatMasker [31], 23.0% of the BssHII sites were
located within repeat sequences in the human genome.
MMSDK libraries using BssHII/NlaIII were generated
from the parental tamoxifen-sensitive cell line MCF-7/
S0.5 and the four TAMR cell lines TAMR-1, TAMR-4,
TAMR-7 and TAMR-8. DNA was isolated from the cell
lines using a DNeasy® Blood & Tissue Kit (Qiagen, Man-
chester, UK) according to the manufacturer’s protocol.
Genomic DNA was digested with BssHII followed by
ligation to biotinylated adaptors and fragmented by NlaIII
(New England BioLabs) cleavage. Because BssHII only cuts
unmethylated regions, binding of DNA fragments to
streptavidin-conjugated magnetic beads allows separation
of unmethylated and methylated fragments. Bound DNA
was ligated to another adaptor N containing the MmeI
restriction enzyme recognition site, and then digested with
MmeI (New England Biolabs), which generates short
sequence tags (16 to 17 bp, due to enzyme cut floating).
The resulting tags were ligated with another adaptor
P7 and amplified by polymerase chain reaction (PCR)
with primers N and P7 for 18 cycles. The five indexed
MMSDK libraries were sequenced in one lane, result-
ing in 1.38 Gb clean tag data for all five cell lines,
with an average sequencing amount of ~270 Mb per
library. A description of the MMSDK method is pro-
vided in Additional file 1. Prior to normalization, the
total number of aligned tags of MMSDK for MCF-7/
0.5, TAMR-1, TAMR-4, TAMR-7 and TAMR-8 were
1,908,177, 2,574,465, 2,556,778, 2,884,094 and 2,650,408,
respectively. On average, 59.5% of the tags with mapping
quality ≥20 were mapped back to the simulated BssHII/
NlaIII reference library, which was used for the subse-
quent analysis.
Digital gene expression tag sequencing
DGE libraries were generated from MCF-7/S0.5, the four
TAMR cell lines, and the LCC1 and LCC2 cell lines. Total
RNA was extracted from the cell lines with TRI Reagent
(Sigma, Brondby, Denmark) according to the manufacturer’s
protocol. The integrity of the extracted RNA was verified by
agarose gel electrophoresis, and the concentration of
RNA was estimated by spectrophotometry. Subsequently,
mRNA was separated from total RNA by poly-T-coated
beads and converted to cDNA. The cDNA was subjected
to NlaIII digestion followed by N-ligation, MmeI digestion,
P7 ligation and PCR to prepare a DGE library in a manner
analogous to that in MMSDK. The PCR products contain-
ing tags from MMSDK and DGE have the same size and
structure since they were generated with the same enzymes
and procedures. Additionally, an index (barcode) system
was developed to allow multiplexed sequencing of samples
for tag profiling through incorporation of barcode se-
quences into the sequences of the adaptor P7.
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quencing with Hiseq 2000 (Illumina, San Diego, CA, USA)
using standard single-end 50-nucleotide sequencing. The
sequences of the adaptors and primers are available in
Additional file 2. The five indexed DGE libraries were
sequenced in one lane, resulting in 1.71 Gb clean tag data
for all five TAMR cell lines, with an average sequencing
amount of ~340 Mb per library. Similarly, the two indexed
DGE libraries for LCC1 and LCC2 were sequenced in
another lane. Prior to normalization, the total number of
aligned tags of DGE for MCF-7/0.5, TAMR-1, TAMR-4,
TAMR-7, TAMR-8, LCC1 and LCC2 were 2,164,460,
2,038,646, 2,047,000, 2,111,546, 1,980,773, 1,583,224 and
3,096,827, respectively. On average, 40.8% of the tags with
mapping quality ≥20 were mapped back to the simulated
NlaIII human transcriptome (refMrna reference library),
which were used for the subsequent analysis.
Accession numbers
The raw data and metadata of DGE and MMSDK for
the MCF-7/S0.5 and four TAMR cell line model were
deposited in the NCBI Gene Expression Omnibus data-
base [GEO:GSE40665].
Statistical and bioinformatic analysis for MMSDK and DGE
Identifying and trimming reads (tags)
According to the experimental design, tags of 16 to 17
nucleotides were mapped together with the neighboring
four nucleotides (the recognition sequence of NlaIII) to
in silico references to reveal the methylation status using
MMSDK analysis, and to reveal the mRNA profile using
DGE analysis. The command line tool FASTX-Toolkit
implemented in Perl was used to trim the adaptor se-
quence [32]. The trimmed tags were subjected to quality
filtering so that only tags with sequencing quality >30
for >80% of the nucleotides were used for subsequent
analysis.
Mapping tags
For tag mapping, we generated a simulated BssHII refer-
ence library by in silico enzyme digestion of the human
genome regardless of the methylation state. This library
was used as a reference for subsequent mapping of
the tags in the MMSDK analysis. In the DGE analysis,
refMrna (hg19; University of California, Santa Cruz
(UCSC), CA, USA) was subjected to in silico digestion
with NlaIII andMmeI and the digested mRNAs were used
as a reference for mapping cDNA tags. Subsequently, the
Burrows-Wheeler Alignment tool (BWA) procedure [33]
allowing one mismatch for aligning the MMSDK and
DGE tags to the simulated BssHII reference library and
the refMrna reference library, respectively, was applied.
For the MMSDK analysis, the genomic locations used
to assess methylation levels were annotated based on thegenomic information of the simulated BssHII reference
library, and the methylation status of each BssHII site
was used to represent the corresponding genomic region
in which this BssHII site was located. The count of the
tags representing a particular BssHII site is a measure of
its degree of nonmethylation in the genome; that is, the
smaller the tag count, the higher the level of methylation
of the site in question. For the DGE analysis, the count
of the tags represents the gene expression level; that is,
the higher the tag count, the higher the expression level.
After mapping and annotating the tags, the data were
normalized by equalizing the total number of tags for all
samples in MMSDK and DGE, respectively. The normal-
ized data were used for the subsequent analysis.
Visualization of MMSDK and DGE data
Integrative Genomics Viewer was used to visualize the
differences between individual tamoxifen-resistant cell
lines and the parental tamoxifen-sensitive cell line MCF-
7/S0.5 with regard to the MMSDK and DGE data [34].
Normalized MMSDK (total 51,918 genomic loci) and
DGE tag (total 19,070 genes) features were used for
visualization. The hg19 human genome was used as a
reference [35]. We defined gene promoters as the re-
gions located in the upstream 2 kb from transcript start-
ing sites (TSSs) and the first exon. We adopted the same
criteria (GC content >50%, ratio of the observed CpGs
to the expected CpGs >0.6, length >200 bp) used by the
UCSC Genome Browser for the definition of CGIs.
Principle component analysis and unsupervised
cluster analysis
Qlucore Omics Explorer 2.3 software (Qlucore, Sweden,
Lund) was used to perform principle component analysis.
Normalized MMSDK (total 51,918 genomic loci) and DGE
tag (total 19,070 genes) data were used as input data for
principle component analyses without filtering. An un-
supervised hierarchical clustering analysis was applied to
analyze the similarities in MMSDK and DGE profiles across
the five TAMR cell model lines using Qlucore Omics
Explorer 2.3 software with a data filter requiring that the
variance/maximum variance of variables across samples is
higher than 0.001. A total of 17,561 genomic loci and 5,220
transcripts passed the filter for unsupervised cluster ana-
lyses, respectively. The Pearson correlation algorithm was
employed for similarity metric calculation. Average linkage
clustering was chosen to organize samples in a tree
structure.
Pathway and enrichment analysis
Ingenuity Pathways Analysis software (Ingenuity Systems,
Redwood City, CA, USA) was used to perform pathway
analysis and uncover related networks for these genes.
Genes showing >2-fold alterations in expression between
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input data in the first analysis. In the second analysis, only
genes exhibiting altered gene expression and inverse
altered methylation levels were included. In addition, an
enrichment analysis using gene set enrichment analysis
[36] to identify over-represented pathways and genes was
performed on genes exhibiting >2-fold alterations in
expression between MCF-7/S0.5 and TAMR cell lines.
Reduced representation of bisulfite sequencing
Gemomic DNA (5 μg) from LCC1 and LCC2 was digested
by the MspI restriction enzyme, (500 U/per sample; New
England BioLabs) overnight at 37°C, and a Mini Purifica-
tion kit (Qiagen) was used to purify the digested products.
End repair was performed, adding A and adaptors, where
the cytosines in the paired end adaptor sequence were
methylated. The ligated product was subjected to size selec-
tion in 2% agarose gel (Bio-RAD, Richmond, CA, USA) at
100 V for 2 hours. Agarose gel bands with 150 to 240 bp
(according to insert DNA size 40 to 120 bp) and 240 to
340 bp (according to the ligated target DNA size 120 to
220 bp), for example, were excised and two libraries
were generated from each sample (one consisting of
40 to 110 bp target sequences and the other of 110 to
220 bp target sequences). DNA from the two excised gel
pieces was recovered by Gel Extraction Purification Kit
(Qiagen), followed by bisulfite treatment using a EZ DNA
Methylation-Gold kit (Zymo Research, Freiburg, Germany).
The resulting converted DNA was amplified by PCR and,
following purification, the reduced representation of bisul-
fite sequencing (RRBS) libraries were generated by perform-
ing paired-end 50-nucleotide sequencing with Hiseq 2000
(Illumina, San Diego, CA, USA). The adaptor sequences
were filtered out from the subsequent analysis and the
resulting reads were aligned using Bismark software [37].
Only uniquely mapped reads with restriction enzyme cut-
ting sites at the 5′ end were used for subsequent methyla-
tion analyses. The sequencing depth and percentage of
methylated cytosines/total investigated cytosines for each
C location were calculated. The genomic annotation
information was based on the hg19 human genome [35].
Gene promoters and CGI were defined using the same
criteria as for the MMSDK analysis. According to the
genomic annotation and coordinates, DNA methylation
information between the TAMR cell line model (MMSDK
data) and the LCC1/LCC2 cell line model (RRBS
data) were compared.
Quantitative reverse transcriptase-PCR validation of
gene expression
Quantitative reverse transcriptase-PCR was performed using
the 2–ΔΔCt method [38]. Briefly, total RNA was extracted
and subjected to DNase I (RNase-free) digestion (Life
Biotechnologies, Paisley, UK) to exclude contaminationfrom genomic DNA. Subsequently, 1 μg purified total RNA
was reverse-transcribed in a final volume of 20 μl containing
10 μl 2× reverse transcriptase buffer (dNTPs and MgCl2),
1 μl random hexamers (300 ng/μl) and 2 μl M-MuLV
RNase H+ reverse transcriptase (DyNAmo Capillary SYBR
Green two-step quantitative reverse transcriptase-PCR kit;
Finnzymes, Thermo Fisher Scientific, Slangerup , Denmark).
cDNA synthesis was conducted by incubation at 25°C for
10 minutes (primer extension), 37°C for 30 minutes, 85°C for
5 minutes (reaction termination) and 4°C hold (sample
cooling). Either β2-microglobulin or pumilio homolog 1
(PUM1) was used as the internal control for normalization
of the data [38]. The SOX2 PCR primer sequence was
obtained from Li and colleagues [39], while primers for
PRKCA and PUM1 were purchased from Qiagen. The
primer design for β2-microglobulin was performed using
Primer3 [40]. Both pairs of primer sequences were blasted
against UCSC Genes in UCSC Genome Bioinformatics using
the In-silico PCR tool to confirm the expected unique ampli-
fication of SOX2 and β2-microglobulin genes, respectively.
The PCR primer sequences are available in Additional file 2.
The quantitative PCR reaction was composed of 2× mas-
ter mix, forward and reverse PCR primer and 0.5 μl 10-fold
diluted cDNA. The analysis was performed in triplicate
using the LightCycler 480 system (Roche, Mannheim,
Germany). A melting curve analysis was performed after
PCR to confirm a single peak (unique amplification) for the
PCR products, which were then run on a 2% electrophoresis
agarose gel to further confirm the presence of a single band
of the expected size. Accurate quantification was confirmed
by generation of calibration curves by serial dilutions (native,
10-fold, 100-fold and 1,000-fold dilution) of one TAMR sam-
ple and MCF-7/S0.5, which showed the same amplification
efficiency of SOX2 and β2-microglobulin, respectively. The
threshold cycle (Ct) number at which the fluorescent signal
is associated with an exponential increase of PCR products
(by default) was used to calculate the normalized target. For
each sample, Δ values were determined by subtracting the
average of triplicate Ct values of the target gene (SOX2)
from that of the reference gene (β2-microglobulin or
PUM1). The relative gene expression level of SOX2 and
PRKCA in each TAMR sample was normalized relative to
the parental MCF-7/S0.5 cell line. The relative expression
levels of the genes were determined by subtracting the aver-
age of triplicate Ct values of the target genes (SOX2 and
PRKCA) from that of the reference genes (β2-microglobulin
or PUM1, respectively). Finally, the relative expression level
(fold-change) of each TAMR sample compared with their
parental cell line (MCF-7/S0.5) was determined using
2–ΔΔCt, in which:
ΔΔCt ¼ Ctgene−Ctreference gene
 
TAMR
– Ctgene−Ctreference gene
 
MCF−7=S0:5
Lin et al. Breast Cancer Research 2013, 15:R119 Page 6 of 17
http://breast-cancer-research.com/content/15/6/R119Results
Visualization and integrative analysis
The MMSDK and DGE profiles of the parental cell line
MCF-7/S0.5 and the four TAMR cell lines were initially
compared and visualized by Integrative Genomics Viewer
(Figure 1A), allowing a global view in a whole human gen-
ome scale of the DNA methylation (MMSDK) and gene
expression (DGE) values in MCF-7/S0.5 as well as alter-
ations between cell lines. For example, detailed informa-
tion on the differences in MMSDK and DGE in the region
centered with FIS1 gene on chromosome 7 is shown in
Figure 1B.
Principal component analysis and unsupervised
cluster analysis
Principle component analysis of the MMSDK data,
which depicts all variables without any a priori classifi-
cation and data filtering in the three-dimensional space,
showed that MCF-7/S0.5 separated from the four TAMR
cell lines, indicating overall differences in global DNA
methylation profiles between parental and resistant cell
lines (Figure 2A). The four TAMR cell lines also separated
from each other, but to a lesser extent than from the
parental cell line. Similarly, principle component ana-
lysis of the DGE data demonstrated a clear separation of
MCF-7/S0.5 from the four TAMR cell lines (Figure 2B).
In unsupervised cluster analysis, MCF-7/S0.5 also sepa-
rated from the four TAMR cell lines for both MMSDK
(Figure 2C) and DGE (Figure 2D).
Overview of DNA methylation alterations between
parental and tamoxifen-resistant sub-lines
DNA methylation analysis revealed that the four TAMR
cell lines exhibited globally higher DNA methylation
levels than MCF-7/S0.5. The distribution of the genomic
loci in different genomic components (counting the
number of tags from given components) is shown in
Figure 3 and Additional file 3. The annotation of the
genomic components is from UCSC. Notably, across all
genomic components as well as in the global view, the
four TAMR cell lines showed higher DNA methylation
levels compared with their parental tamoxifen-sensitive
cell line.
Genes exhibiting altered expression between parental and
tamoxifen-resistant sub-lines in the TAMR cell line model
Initially, we investigated the expression levels of ESR1,
ESR2, PGR, IGF1R, PTEN, ERBB2 (HER2), PRKCA and
NOTCH3, which were previously implicated in tamoxi-
fen resistance. There was no significant difference in the
expression of ESR1, but slightly increased expression of
ESR2 (2.3-fold) was observed. ERRB2 (3.8-fold), PRKCA
(2.6-fold) and NOTCH3 (6.9-fold) also exhibited increased
expression in TAMR versus MCF-7/S0.5 cell lines, whileexpression of PGR (−32.1-fold), IGF1R (−3.7-fold) and
PTEN (−10.2-fold) was decreased. Generally, these results
using DGE tag sequencing were consistent with those of
previous studies [11,41,42]. The slight difference in the ex-
pression levels of ESR1 and ESR2 in the current study
compared with previous studies could be due to differences
in methodologies. Further investigation of key cell cycle
genes such as MYC and CCND1 (cyclin D1) showed that
these genes remained highly expressed in all resistant
sub-lines, but there was no significant difference (MYC
1.0-fold) and only slightly lower levels (CCND1 –1.8-fold
change) in TAMR versus MCF-7/S0.5 cell lines.
Next, we investigated the expressed genes that exhib-
ited >2-fold altered expression common for all TAMR
cell lines versus MCF-7/S0.5 and identified 3,063 genes, of
which 1,561 were expressed at higher levels (Additional
file 4) and 1,502 at lower levels (Additional file 5) in
TAMR cell lines versus MCF-7/S0.5.
Interestingly, several of the altered genes related to
pluripotency and differentiation, including SOX2, which
exhibited higher expression levels (74.8-fold) in TAMR
cell lines versus MCF-7/S0.5 (Figure 4). The whole SOX
gene family was further studied and showed decreased ex-
pression of SOX3 (−17.3-fold), SOX4 (−51.6-fold), SOX9
(−12.8-fold) and SOX13 (−54.3-fold) in TAMR cell lines
versus MCF-7/S0.5 (Figure 4), while the remaining SOX
genes were not expressed or exhibited very low expression
in both TAMR cell lines and MCF-7/S0.5 (data not shown).
We also observed alterations of the expression of E2F gene
family, with decreased expression of E2F1 (−57.6-fold) and
E2F3 (−44.9-fold) and elevated expression of E2F2 (7.3-
fold) in TAMR cell lines versus MCF-7/S0.5, while expres-
sion of E2F4 was not significantly altered (1.6-fold). The
expression levels of E2F1, E2F2 and E2F3 were consider-
ably lower than E2F4 in all cell lines. Since E2F interacts
with RB-related pocket proteins (p130 and p105), we also
investigated the expression of these two pocket protein
genes. RBL2 (p130) exhibited higher expression than
NFKB1 (p105) in all cell lines. Further, RBL2 and FOXA1
also showed higher expression (2.4-fold and 2.9-fold, re-
spectively), while NFKB1 showed decreased expression
(−3.2-fold) in TAMR cell lines versus MCF-7/S0.5. Taken
together, altered expression of pluripotency and differenti-
ation genes, including increased expression of SOX2,
decreased expression of other SOX gene families, and alter-
ations of the expression of E2F genes and pocket protein
genes, may suggest a role for cancer-initiating cells/cancer
stem-like cells in tamoxifen resistance.
Relationship between DNA methylation and gene expression
in parental and tamoxifen-resistant sub-lines in the TAMR cell
line model
Initially, we delineated the global impact of DNA methyla-
tion on gene expression by classifying all genes into three
Figure 1 Global landscape of the differences in modified DNA methylation-specific digital karyotyping and digital gene expression profiles for
the parental MCF-7/S0.5 and the four TAMR cell lines as visualized by Integrative Genomics Viewer. The x axis shows the locations in the whole
human genome (A) and the region of FIS1 on chromosome 7 (B). The height of the bars in modified DNA methylation-specific digital karyotyping
(MMSDK) for MCF-7/S0.5 (red) shows the extent of the number of tags representing the frequency of nonmethylated CpG islands at the particular locus.
The MMSDK data for the four TAMR cell lines is expressed as the difference in expression between a given TAMR and the parental cell line (red/blue).
The height of the bars in digital gene expression (DGE) for MCF-7/S0.5 (green) is proportional to the gene expression level. The DGE data for the four TAMR
cell lines are expressed as the difference in expression between a given TAMR cell line and the parental cell line (green/blue).
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http://breast-cancer-research.com/content/15/6/R119groups based on gene expression levels: low (0 to 1 tag);
intermediate (2 to 50 tags); and high (>50 tags). Accord-
ingly, DNA methylation loci were also classified into four
groups according to methylation levels: very high (0 to 1
tag); high (2 to 10 tags); intermediate (11 to 70 tags); and
low (>71 tags).Since the impact of DNA methylation on gene expression
is known to depend on the genomic location relative to the
TSS, plots were generated showing the global positional
relationship between DNA methylation and gene expres-
sion at different expression levels (Figure 5 and Additional
file 6). The plots demonstrate a relationship between DNA
Figure 2 Principle component analysis and unsupervised cluster analysis for DNA methylation and gene expression data in TAMR and
MCF-7/S0.5 cell lines. Principle component analysis results for modified DNA methylation-specific digital karyotyping (MMSDK) (A) and digital
gene expression (DGE) (B) data show that the TAMR cell lines grouped separately from the parental MCF-7/S0.5 cell line. The unsupervised cluster
analyses of MMSDK (C) and DGE (D) also show clear separation of TAMR cell lines from the MCF-7/S0.5 cell line.
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http://breast-cancer-research.com/content/15/6/R119methylation and distance to TSS locations, with the lowest
DNA methylation level being at the TSS region across all
gene expression levels. Comparing DNA methylation levels
between the groups showed an inverse relationship be-
tween gene expression and DNA methylation levels; that is,
higher methylation levels were associated with lower gene
expression levels. Second, we investigated in detail the rela-
tionship between DNA methylation and gene expression inindividual genes of interest. Figure 4 shows plots of mRNA
expression, DNA methylation and genomic location for
genes of interest, including the SOX gene family (Figure 4).
A panel of 44 genes were found to exhibit higher pro-
moter CGI DNA methylation (twofold change) in TAMR
cell lines versus MCF-7/S0.5 cells, with concurrent lower
gene expression (twofold change) in TAMR cell lines versus
MCF-7/S0.5. Among these genes, NRIP1, HECA and FIS1
Figure 3 Distribution of DNA methylation levels of different genomic components in MCF-7/S0.5 versus TAMR cell lines. MCF-7/S0.5
shows low DNA methylation levels compared with TAMR cell lines in both the global profile and the different genomic components (CpG island
(CGI), CGI shore, gene, promoter and exon). The x axis shows the color-coded methylation states of CpGs for the MCF-7/S0.5, TAMR-1, TAMR-4,
TAMR-7 and TAMR-8 cell lines. The mean methylation state of CpGs is categorized into very high (grey, 0 to 1 tag), high (blue, 2 to 10 tags), intermediate
(orange, 11 to 100 tags), and low (yellow >100 tags). The y axis shows the proportion of CpGs covered by methylation scores at low, intermediate, or
high levels. Coordinates for genomic features were taken from the University of California, Santa Cruz genome database, with the exception of CGI
shores, which were defined as 2 kb on either side of the CGI.
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http://breast-cancer-research.com/content/15/6/R119were of particular interest since they have previously been
reported to be associated with breast cancer pathogenesis.
Another set of 18 genes exhibited lower promoter CGI
DNA methylation (twofold change) in TAMR cell lines
versus MCF-7/S0.5 cells, with concurrent higher gene
expression (twofold change) in TAMR cell lines versus
MCF-7/S0.5. The DNA methylation state of promoters
with and without CGIs for the genes that exhibited altered
expression in TAMR cell lines versus MCF7/S0.5 is listed in
Additional files 7 and 8.
Pathway analysis
To further elucidate the pathways affected in connection
with tamoxifen resistance in breast cancer, we performed
pathway analysis of genes exhibiting altered methylation of
promoter sites in TAMR versus MCF-7/S0.5 cells and con-
current inverse alteration of gene expression levels using the
Ingenuity Pathway Analysis software (Ingenuity Systems,
Redwood City, CA, USA). Among the genes with significant
DNA methylation loci, we observed significant enrichment
of genes associated with cell cycle, cellular growth andproliferation, including FOS, LMNA, RUNX1, SLC9A3R1,
SNTB2, STAT5B, SUZ12, UGCG, VEGFA, AK4, NCOA6,
NCOR2, SOX4, EPB41L1, EHD1 and SNTB2. This suggests
an important role in tamoxifen resistance of epigenetic alter-
ation of genes involved in growth and proliferation of cancer
cells. Similarly, analysis of differentially expressed genes
identified by mRNA sequencing showed significant enrich-
ment of genes associated with cell cycle, cellular assembly
and organization, DNA replication, cell survival and death
as well as cell proliferation. These genes included BACE1,
CADM1, CCNA2, CDC42SE1, CDKN2C, CDKN3, CDT1,
CENPE, CKS2, COL7A1, CTGF, DAAM1, ERBB2, ERRFI1,
GLO1, LAMP2, MKI67, MLXIP, MYBL1, MYBL2, MYO10,
NEK2, OSMR, POLE2, PRC1, RAB31, RAD51AP1, RALB,
RHOD, SOLH, SOX4,TGFB1,THBS1,WNT5B and ZWINT.
The canonical pathways with significant gene enrichment
included the RAR activation and the DNA damage response
pathways. In addition, pathways such as Notch, Wnt/
β-catenin and transforming growth factor beta signaling,
which are known for extensive cross-talk and are implicated
in stemness, were shown to be associated with genes that
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Figure 4 Relationship between the state of DNA methylation and gene expression for individual genes. Gene expression and DNA
methylation states around transcription start sites (TSSs) are presented for selected genes. To the left of each panel, the height of the bar
represents the gene expression level (normalized tag number of digital gene expression (DGE) data), while the line in the right panels shows
DNA methylation levels for the genomic loci around TSSs.
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http://breast-cancer-research.com/content/15/6/R119showed differential expression patterns between TAMR and
MCF-7/S0.5 cells. Finally, gene set enrichment analysis of
our expression data demonstrated enrichment of the pluripo-
tency and differentiation processes, as well as the E2F family
(Additional file 9). E2F1, E2F2, F2F3, RBL2 (p130) and
NFKB1 (p105) were enriched in the gene sets of KEGG_
PANCREATIC CANCER and KEGG_CELL_CYCLE using
the gene set enrichment analysis database. SOX3 and SOX4
were enriched in the gene set MASSARWEH_TAMOXIFEN_
RESISTANCE_DN.Validation of methylation, gene expression and pathway
alterations in the LCC1/LCC2 cell line model
To ensure that the alterations observed in TAMR cell lines
versus MCF-7/S0.5 cells were not unique to this specific
cell line model, we examined whether the methylation, gene
expression and pathway alterations associated with TAMR
could be observed in another tamoxifen-resistant cell line
model, LCC1/LCC2. DNA methylation analysis of LCC1
and LCC2 was performed by RRBS, and the results werecompared with the DNA methylation profile of TAMR ac-
cording to genomic coordinates. The two cell line models,
in general, exhibited global inherited DNA methylation
profiles, reflecting their biological origins. In addition, the
two cell line models shared several DNA methylation alter-
ations. Further, many genes that exhibited altered gene ex-
pression in the TAMR cell line model inversely correlated
with DNA methylation and were also identified in the
LCC1/LCC2 cell line model (Figure 6 and Additional files
10 and 11). Some important genes, such as PGR, CCND1,
MYC, PTEN, SOX4, SOX13 and TGFβ1, and pathways such
as transforming growth factor beta signaling that are impli-
cated in tamoxifen resistance in the TAMR cell line model
were also identified in the LCC1/LCC2 cell line model.Validation of SOX2 and PRKCA gene expression
The higher gene expression levels of SOX2 and PRKCA in
TAMR cell lines versus MCF-7/S0.5 obtained by sequencing
were further evaluated by quantitative reverse transcriptase-
PCR and confirmed that the relative expression of
Figure 5 Relationship between DNA methylation and gene expression in MCF-7/S0.5 and TAMR1. An inverse relationship between DNA
methylation and gene expression levels is noted. The expressed genes are grouped according to expression levels: low (left), moderate (middle)
and high (right). Dark blue, light blue, orange and yellow present extreme-high, high, medium and low DNA methylation levels. The x axis shows
the genomic location relative to the transcriptional start site. The y axis shows the percentage of methylation for a given genomic location.
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http://breast-cancer-research.com/content/15/6/R119both SOX2 and PRKCA in all four TAMR cell lines was sig-
nificantly higher than in MCF-7/S0.5 (Figure 7). The
expression level of SOX2 was particularly high in TAMR-8.Discussion
Tamoxifen has a great impact on clinical management of
breast cancer; however, about one-third of early-stage
breast cancer patients eventually experience disease recur-
rence and subsequent mortality [7]. Resistance to tamoxifen
is thus a major clinical issue and considerable efforts have
been made to elucidate the mechanisms leading to this re-
sistance, including decrease or loss of ERα expression that
could result from mutations of the ESR1 gene, and/or
hypermethylation of the ESR1 gene promoter, altered
expression of ERβ protein, endocrine adaptation, pharma-
cologic tolerance (for example, increased metabolism of
tamoxifen to agonistic metabolites), altered patterns of co-
regulator (co-activator and co-repressor) expression, cross-
talk between ERα and growth factor signaling pathway, or
influence of the phosphoinositide 3-kinase cell survival
pathway and interaction between ER protein with thestress-activated protein kinase/c-junNH2 terminal kinase
pathway [6,7].
Several distinct mechanisms may lead to tamoxifen resist-
ance, and within individual tumors different cancer cells
may use different mechanisms, complicating evaluation of
tamoxifen resistance mechanisms in whole tumor samples.
To simplify the matter, we used a cell line model wherein
ER-positive MCF-7/S0.5 cells were exposed to high-dose
tamoxifen resulting in tamoxifen-resistant TAMR cell lines.
Our TAMR cell lines seem to mimic the clinical situation
wherein tumors are exposed to high doses of tamoxifen
that eradicate the majority of cells, but a few cells may sur-
vival and lead to relapse and therapy failure. In addition, an
independent tamoxifen-resistant cell line model (LCC1/
LCC2), which mimics another clinical situation wherein
tumors are exposed initially to insufficient dosages of tam-
oxifen, was used to verify the finding in the TAMR cell line
model. Our next-generation sequencing of mRNA from
both cell line models revealed that many genes associated
with cancer stem cells exhibit altered expression in resistant
versus parental cell lines. Increasing evidence supports the
hypothesis that these resistant cells arise from putative
Figure 6 Overlap between methylation and gene expression
alterations in the TAMR and LCC cell line models. (A) Venn diagram
showing the overlapping number of genes that exhibited altered
expression (twofold change) in both the TAMR versus MCF-7/S0.5 and
the LCC2 versus LCC1 cell line models. (B) Venn diagram showing the
overlapping number of genes that exhibit altered promoter CpG
island (CGI) DNA methylation (twofold change) and concurrent
inversely altered gene expression (twofold change) in both the TAMR
versus MCF-7/S0.5 and the LCC2 versus LCC1 cell line models.
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http://breast-cancer-research.com/content/15/6/R119cancer-initiating cells or cancer stem-like cells. For ex-
ample, tamoxifen treatment in combination with targeted
cancer stem cell inhibition achieves a better outcome than
tamoxifen treatment alone, indicating that surviving cancer
stem-like cells may remain viable after initial endocrine
therapy [24]. In situ observations have identified candidate
cells with stem cell-like features of various phenotypes in
breast cancer samples [24], and it has been suggested that
such cells may be responsible for therapeutic failures
[43-45].
In our study, we found high expression of SOX2 in the
TAMR cell lines. SOX2 is a transcription factor essential for
maintaining self-renewal of undifferentiated normal embry-
onic stem cells, and also plays an important role in cancerdevelopment and recurrence [46]. In addition, SOX2 is
one of the four factors that, by induction, can induce pluri-
potent stem cells from mouse embryonic or adult
fibroblasts [47]. In fact, the expression of the SOX2 gene in
itself could be responsible for stem cell properties [46].
SOX2 has been shown to be expressed in early-stage breast
tumors, while expression of other normal stem cell
markers, such as OCT4 or NANOG, was not observed.
Furthermore, the expression of SOX2, but not OCT4 or
NANOG, induced mammosphere formation in cultures,
underscoring the possibility that increased expression of
SOX2 is sufficient to induce cancer stem cell properties
[46]. Interestingly, a recent study showed that TAMR cells
exhibited increased mammosphere-forming capability com-
pared with MCF-7/S0.5 cells (8% vs. 3%) [48]. Additionally,
the promoting role of SOX2 in cell proliferation mediated
through CCND1 (cyclin D1) has been demonstrated by gain-
of-function and loss-of-function experiments using MCF-7
cells [48]. The positive correlation of the co-expression of
SOX2 and CCND1 with tumorigenesis has also been
demonstrated in clinical breast cancer samples [49].
In contrast to SOX2, several other members of the SOX
family (SOX3, SOX4, SOX9 and SOX13) showed decreased
expression in the resistant versus parental cell lines.
These SOX gene family members play important roles in
differentiation and tissue maturation [50], and have also
been implicated in regulating β-catenin activity [51-54].
Since the majority of SOX genes negatively regulate Wnt/
β-catenin signaling, their expression (in contrast to SOX2
[55]) could suppress the activity of cyclin D1. Decreased
expression of these genes could thus attenuate their
suppressing effect on proliferation. Taken together, SOX2
and the other SOX family members activate the expression
of MYC and CCND1, perhaps bypassing the blocked ER-
mediated mitogenesis by which cancer cell proliferation
can be maintained.
We also identified alterations in the expression of the
E2F gene family, which strengthens the association of stem-
ness features with the development of tamoxifen resistance.
The E2F gene family of transcription factors provides
important downstream effector functions in a pathway that
controls the expression of genes involved in cell cycle pro-
gression, G1/S transition and DNA replication [56]. Becker
and colleagues demonstrated that human stem cells differ
from somatic cells in the expression of members of the E2F
family and RB-related pocket proteins [57]. They reported
that human stem cells and teratocarcinoma cells show a se-
lective reduction in the expression of E2F1, E2F2, E2F3 and
p105 (encoded by NFKB1) and enhanced expression of
E2F4, E2F5, E2F6 and p130 (encoded by RBL2) compared
with human normal somatic IMR90 cells [57]. In our study,
decreased expression of E2F1 E2F3 and NFKB1 (p105) and
increased expression of RBL2 (p130) was observed in the
tamoxifen-resistant versus parental cell lines. Moreover,
Figure 7 Relative expression of SOX2 and PRKCA in the MCF-7/S0.5 and TAMR cell lines. Comparison of the relative expression of SOX2 and
PRKCA genes (fold-changes) in the four TAMR cell lines compared with their parental cell line MCF7/S0.5.
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http://breast-cancer-research.com/content/15/6/R119RBL2 (p130) showed higher expression levels than NFKB1
(p105), and E2F4 showed higher expression levels than
E2F1, E2F2 and E2F3 in all five cell lines. This observation
further supports the role of cancer-initiating cells/cancer
stem-like cells in the development of resistance to tamoxi-
fen treatment.
NOTCH3, which has been shown to play a role in main-
tenance of stemness in breast cancer cells, was also more
highly expressed in the tamoxifen-resistant versus parental
cell lines. NOTCH3 has been shown to be upregulated
when normal breast tissue is grown as mammospheres
[58], and downregulation of NOTCH3 by short hairpin
RNA interference in MCF-7 cells reduced the capacity offirst-generation mammospheres to produce a second gen-
eration [59]. NOTCH3 was also found to be upregulated
in CD44+ populations of normal cells and breast cancer
cells [60].
In addition to gene expression alterations, we also deter-
mined DNA methylation levels in the resistant and parental
cell lines using MMSDK. In a global view, our data show
that high DNA methylation in the neighborhood of tran-
scription start sites correlated with lower gene expression.
A large panel of genes was found to exhibit higher
promoter CGI DNA methylation in the resistant versus
parental cells and concurrent lower gene expression in the
resistant versus parental cells. Among these genes, NRIP1,
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http://breast-cancer-research.com/content/15/6/R119HECA and FIS1 were of particular interest because they
have previously been reported to be associated with breast
cancer pathogenesis [61-63], and further studies of these
genes will be pursued. Our results differ somewhat from
those of an earlier study that examined the gene expression
and methylation status of a single tamoxifen cell line
[22]. For example, Fan and colleagues found that their
tamoxifen-resistant cell line was associated predominantly
with global promoter hypomethylation relative to the
parental line [22], while, in contrast, we observed global
hypermethylation of all four tamoxifen-resistant versus
parental cell lines. However, one should note that the
tamoxifen-resistant cell line generated by Fan and col-
leagues [22] was derived from a different strategy than our
four tamoxifen-resistant cell lines, and the technology used
to analyze gene and methylation levels also differed (array
vs. sequencing).
DGE, as used in our study to investigate gene expression,
is a common method that exhibits high fidelity. DGE
captures the sequence from the 3′ end of transcripts,
thereby avoiding involvement of complex statistical model
to address isoform splicing events for estimating gene
expression. MMSDK, as we used to examine the DNA
methylation profiles, is also a reliable method as shown in
an earlier study where the results identified by MMSDK
could be validated by quantitative PCR-based and bisulfite
clone sequencing [25]. In addition, to avoid putativeFigure 8 A possible mechanism implicated in tamoxifen resistance in
estrogen receptor (ER) and prevents binding between estradiol and ER, thereb
remains high due to direct activation mediated by SOX2 and/or by the Wnt/β-
SOX gene family members on this pathway. Transforming growth factor beta (
(cyclin D1). Cyclin D1 interacts with pocket proteins (Rb, P105 and P130) and ab
G1/S transition. By this mechanism, the cancer cells may bypass the blocked esinfluence of PCR amplification bias, PCR amplification was
limited to a maximum of 18 cycles.
In our study, not all genes exhibiting altered gene expres-
sion also exhibited corresponding promoter methylation
changes, perhaps due to the resolution of the MMSDK
method that did not identify all methylation alterations. For
some individual genes, the MMSDK sampling locations
(BssHII recognition sites) are still limited. Many SOX family
genes and E2F family genes have no BssHII site in their
promoter and enhancer regions, limiting our analysis of
methylation alterations in these genes. In addition, for
many genes more than one methylation site was examined,
some of which exhibited altered expression while others
did not. It is not currently known which of the sites are of
functional importance. Finally, some genes of interest in
our study, such as SOX2, did not show any impact of DNA
methylation on gene expression (according to BssHII recog-
nition sites on its promoter region), which does not exclude
the possibility of the impact of DNA methylation status of
other cis-regulatory element(s) on the expression of SOX2.
Further studies are needed to confirm this hypothesis.
Notably, FOXA1, a pioneer factor in development and
differentiation [64,65], has been suggested to interact with
hormonal receptors (ER and androgen receptor) and play a
role in breast cancer and prostate cancer, and even in
tamoxifen resistance [66-69]. Our results suggest an associ-
ation between reprogramming transcription, epigeneticthe TAMR cell line model. While tamoxifen competitively binds with
y blocking estrogen mitogenetic activity, CCND1 (cyclin D1) expression
catenin pathway through attenuation of the suppression effect of other
TGFβ) and Notch pathways are also implicated in activation of CCND1
rogates their suppressive effect on E2F. Finally, activated E2F accomplishes
trogen-mediated mitogenesis and maintain proliferation.
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http://breast-cancer-research.com/content/15/6/R119plasticity and tamoxifen resistance. The precise mechanism
and profound role of this gene require further investigation.
Conclusion
High expression of SOX2 and suppression of other SOX
gene family members in combination with usage of the
E2F gene family, RB-related pocket protein genes and
highlighted stem-like cell-associated pathways implies
that cancer-initiating cells/stem-like cells may be crucial
for development of resistance to tamoxifen (Figure 8).
Large differences in global gene expression and DNA
methylation profiles between the parental MCF-7
tamoxifen-sensitive human breast cancer cell line and
its high-dosage tamoxifen-selected resistant subpopula-
tions were observed. In general, DNA methylation in
promoter regions is shown to be associated with repres-
sion of gene expression, which also holds true for some
genes previously associated with breast cancer develop-
ment. Thus, although tumor-initiating cells/stem-like
cells may be of primary importance, these cells might
acquire survival advantage in gene expression via
epigenetic mechanisms. However, it is difficult to prove
this hypothesis because even the stemness-associated
genes can be regulated by epigenetic changes and the
present techniques do not allow the DNA methylation
status of tamoxifen-selected resistant cells at the single
cell level to determined (each sub-line TAMR was devel-
oped from such single surviving cells). In this study,
biological replicates were not sequenced. Although the
results of DNA methylation and gene expression from
the four individual tamoxifen-resistant TAMR cell lines
were highly consistent, further analysis using ap-
proaches with higher coverage, such as RRBS and RNA
Seq, may confirm our findings.
Our results underscore the likelihood of stem cell-like re-
sistant cells in tamoxifen resistance. The present study
shows some evidence of stemness and cell plasticity in
tamoxifen-resistant cells and poses a new hypothesis link-
ing cell fate plasticity, epigenetic programming, and pos-
sible induced pluripotency processes with tamoxifen
resistance. To prove our hypothesis and deepen under-
standing of the mechanism of drug resistance more infor-
mation from genomic, epigenomic and transcriptomic
analyses will be required, as well as deciphering cross-talk
between these mechanisms in cancer cells.
Additional files
Additional file 1: Presents a description and illustration of the
MMSDK method.
Additional file 2: Lists the sequence of adaptors and primers used
in this study.
Additional file 3: Is a figure showing the distribution of DNA
methylation levels of various genomic components in MCF-7/S0.5versus TAMR cell lines. MCF-7/S0.5 shows low DNA methylation levels
compared with TAMR cell lines in the different genomic components
(intron, LTR (long terminal repeat), SINE (short interspersed elements),
LINE (long interspersed elements), LINE1, LINE2, and satellite). The x axis shows
the color-coded methylation states of CpGs for the MCF-7/S0.5, TAMR-1,
TAMR-4, TAMR-7 and TAMR-8 cell lines. The mean methylation state of CpGs
is categorized into very high (gray, 0 to 1 tag), high (blue, 2 to 10 tags),
intermediate (orange, 11 to 100 tags), and low (yellow >100 tags). y axis shows
the proportion of CpGs covered by methylation scores at low, intermediate, or
high levels. Coordinates for genomic features were taken from the UCSC
genome database and LINEs are defined by RepeatMasker.
Additional file 4: Is a table listing the genes exhibiting higher
expression (>2-fold) in TAMR cell lines versus MCF-7/S0.5. To avoid
the influence of large variance in low-expressed genes, expression
levels <10 tags have been binned to 10 tags.
Additional file 5: Is a table listing the genes exhibiting lower
expression (≤2-fold change) in TAMR cell lines versus MCF-7/S0.5.
To avoid the influence of large variance in low-expressed genes, expression
levels <10 tags have been binned to 10 tags.
Additional file 6: Is a figure showing the relationship between DNA
methylation and gene expression in TAMR-4, TAMR-7 and TAMR-8.
An inverse relationship between DNA methylation and gene expression
levels is noted. The expressed genes are grouped according to
expression levels: low (left), moderate (middle) and high (right). Dark
blue, light blue, orange and yellow represent extreme-high, high,
medium and low DNA methylation levels, respectively. The x axis shows
the genomic location relative to the TSS. The y axis shows the percentage
of methylation for a given genomic location.
Additional file 7: Is a table listing the genes exhibiting lower
expression (≤2-fold change) and concurrent higher DNA methylation
(≤2-fold change in MMSDK data) in the promoter CGI region in TAMR
cell lines versus MCF-7/S0.5.
Additional file 8: Is a table listing the genes exhibiting higher
expression (>2-fold change) and concurrent lower DNA methylation
(>2-fold change in MMSDK data) in the promoter CGI region in
TAMR cell lines versus MCF-7/S0.5.
Additional file 9: Is a table listing the gene set enrichment analysis
identifying over-represented pathways.
Additional file 10: Is a table listing the genes exhibiting altered
expression (upregulated or down regulated, absolute value >2-fold
change) in both the TAMR versus MCF-7/S0.5 and the LCC2 versus
LCC1 cell line models.
Additional file 11: Is a table listing the genes exhibiting altered
expression (upregulated and down regulated, absolute value >2-fold
change) and concurrent inversely altered DNA methylation in the
promoter region in both the TAMR versus MCF-7/S0.5 and the LCC2
versus LCC1 cell line models.
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